Sarcomatoid Carcinoma in the Parotid Gland: A Review of 30 Years of Experience

Laryngoscope. 2019 May;129(5):1137-1140. doi: 10.1002/lary.27474. Epub 2018 Aug 27.

Abstract

Objective: The goal of this study was to analyze the results of clinical treatment of sarcomatoid carcinoma in the parotid gland by reviewing 30 years of experience.

Methods: Thirty-five patients were enrolled in this study. The Kaplan-Meier methods were used to calculate the recurrence-free survival (RFS) and disease-specific survival (DSS) rates. The Cox model was used to determine the independent risk factor.

Results: Mean age at presentation was 57.8 years, and most of the patients were staged as tumor (T)3 or T4. Perineural invasion was noted in 15 (42.9%) patients. Fifteen (42.9%) patients received neck dissection due to clinically suspicious nodes. Of those, three patients had pathologically positive nodes. Recurrence was noted in 14 patients; the most common pattern of treatment failure was local recurrence, and only 40% of the patients could receive salvaged surgical treatment. Disease-specific death was noted in 10 patients. The 5-year RFS and DSS rates were 67.3% and 65.7%, respectively. In a multivariate analysis, only the factor of perineural invasion was independently correlated with death.

Conclusion: Parotid sarcomatoid carcinoma carries a poor prognosis, and perineural invasion was the most important predictive factor.

Level of evidence: 2b Laryngoscope, 129:1137-1140, 2019.

Keywords: Sarcomatoid carcinoma; head and neck cancer; parotid cancer; parotid gland.

MeSH terms

  • Adult
  • Aged
  • Carcinoma / pathology
  • Carcinoma / surgery
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parotid Neoplasms* / pathology
  • Parotid Neoplasms* / surgery
  • Prospective Studies
  • Time Factors
  • Treatment Outcome